how to start taking semaglutide Stop Rebound Weight Gain After How Do You Know When

Testosterone, the key male hormone, affects everything from muscle mass and bone density to libido and mood

Nrf2 Regulates Granuloma Formation and Macrophage Activation during Mycobacterium avium Infection via Mediating Nramp1 and HO-1 Expressions

What the Evidence Actually Shows At a glance Microdosing GLP-1s typically means using 0.25 mg or 0.5 mg semaglutide long-term instead of titrating to 2.4 mg STEP-1 showed 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg, not with sub-therapeutic doses SURMOUNT-1 showed up to 22.5% weight loss with tirzepatide 15 mg at 72 weeks No published RCT has tested a "microdosing" protocol for weight management The 0.25 mg semaglutide starting dose is a tolerability ramp, not a treatment dose GI side effects (nausea, vomiting) are the main driver of patient interest in lower doses Weight regain after GLP-1 discontinuation averaged two-thirds of lost weight by 1 year in the STEP-1 extension The FDA-approved maintenance dose for chronic weight management is semaglutide 2.4 mg weekly or tirzepatide 5 to 15 mg weekly Cost savings from microdosing are real but come with proportionally reduced clinical benefit What "Microdosing" GLP-1s Actually Means The term "microdosing" has no formal pharmacological definition when applied to GLP-1 receptor agonists

We thank all the participants and carers for their generous participation in the study